The study explored the cost-consequences of adding examination with Hexaminolevulinate (HAL) and blue light in flexible cystoscopy to the regular follow-up during the first year in an outpatient setting in Sweden. Use of Hexvix® in follow-up of all risk groups has minimal cost impact in a 5-year perspective and is cost saving from year 2 onwards, compared to examination with white-light only. The budget impact was estimated to +1,6% total cost over 5 years, or SEK 189 per patient per year. Time is freed up in the operating room and the number of bed days is reduced over the 5-year period.
The study was published March 15. Read more here
See Future Oncology current issue here
Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden. Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor. Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate- and high-risk groups from year 2.Conclusion: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.